MonumenTAL-2: This phase I study is evaluating how safe and tolerable a targeted therapy (talquetamab) is when administered in different combinations with other cancer drugs (including carfilzomib, daratumumab, lenalidomide and pomalidomide) in people with multiple myelomaA Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Summary

This is a non-randomised trial that has five experimental arms. In Experimental Arm A, participants will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion. In Experimental Arm B, participants will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion. In Experimental Arm C, participants will receive talquetamab SC in combination with lenalidomide orally. In Experimental Arm D, participants will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally. In Experimental Arm E, participants will receive talquetamab SC in combination with pomalidomide orally.